Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.45 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944614 | 0.82 | MMP1 (0.51) | — | |
| SCHEMBL1946591 | 0.79 | ALDH1A1 (0.50) | ALDH1A1EPHX2HPGD | |
| SCHEMBL1670666 | 0.78 | KMT2A (0.67) | RAB9AALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1948127 | 0.78 | SPHK2 (0.45) | ALDH1A1GAAEPHX2HPGD | |
| SCHEMBL1945586 | 0.77 | MEN1 (0.44) | RAB9AALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1945575 | 0.77 | POLB (0.52) | RAB9AKMT2ASMN1; SMN2GAAHPGD | |
| SCHEMBL10131753 | 0.75 | CCR2 (0.56) | RAB9AALDH1A1MEN1KMT2ATAOK1 | |
| SCHEMBL16607158 | 0.69 | KMT2A (0.67) | RAB9AALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5650437 | 0.69 | MEN1 (0.58) | RAB9AALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10131857 | 0.69 | RAB9A (0.67) | RAB9ACCR2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130414-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130414-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TPMT, ABCG2, TALDO1 | RAB9A 2924/4885ALDH1A1 1158/4885MEN1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.